key: cord-0766741-krumnhrc
authors: Galanis, Petros; Vraka, Irene; Fragkou, Despoina; Bilali, Angeliki; Kaitelidou, Daphne
title: Seroprevalence of SARS-CoV-2 antibodies and associated factors in health care workers: a systematic review and meta-analysis
date: 2020-11-16
journal: J Hosp Infect
DOI: 10.1016/j.jhin.2020.11.008
sha: 09ddcc311d3cc2d1d810a77d4ecc2fe89b075c62
doc_id: 766741
cord_uid: krumnhrc

BACKGROUND: Health care workers (HCWs) represent a high risk population for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. AIM: To determine the seroprevalence of SARS-CoV-2 antibodies among HCWs, and to find out the factors that are associated with this seroprevalence. METHODS: The Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines were applied for this systematic review and meta-analysis. Databases including PubMed/MEDLINE and pre-print services (medRχiv and bioRχiv) were searched from inception up to August 24, 2020. FINDINGS: Forty-nine studies, including 127,480 HCWs met the inclusion criteria. The estimated overall seroprevalence of SARS-CoV-2 antibodies among HCWs was 8.7% (95% CI: 6.7-10.9%). Seroprevalence was higher in studies that were conducted in North America (12.7%) compared to those in Europe (8.5%), Africa (8.2), and Asia (4%). Meta-regression showed that increased sensitivity of antibodies test was associated with increased seroprevalence. The following factors were associated with seropositivity: male gender, Black, Asian, and Hispanic HCWs, work in a coronavirus disease 2019 (COVID-19) unit, patient-related work, frontline health care workers, health care assistants, personal protective equipment shortage, self-reported belief for previous SARS-CoV-2 infection, previous positive polymerase chain reaction test, and household contact with suspected or confirmed COVID-19 patients. CONCLUSION: The seroprevalence of SARS-CoV-2 antibodies among HCWs is high. Excellent adherence to infection prevention and control measures, sufficient and adequate personal protective equipment, and early recognition, identification and isolation of HCWs that are infected with SARS-CoV-2 are imperative to decrease the risk of SARS-CoV-2 infection.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 2019 (COVID-19) emerged from the Wuhan, Hubei province, China during December 2019

The main characteristics of the 49 studies included in our systematic review and metaanalysis are shown in Table 1 . A total of 127,480 HCWs were included in this systematic review and meta-analysis. Forty-nine studies reported data regarding the seroprevalence of SARS-CoV-2 antibodies among HCWs and 27 studies [14, 15, 18, 19, 21-25, 27-32, 34-37, 39, 44, 47, 52, 54, 58, 60, 61] investigated factors for SARS-CoV-2 antibodies positivity.

The majority of studies was conducted in Europe (n=31), and then in North America (n=9), Asia (n=6), and Africa (n=3). In particular, nine studies was conducted in USA [14, 15, 24, 26, 27, 29, 32, 34, 40] , eight studies in Italy [23, 28, 30, 36, 44, 45, 56, 57] , seven studies in United Kingdom [16, 17, 20, 25, 33, 59, 61] , five studies in Germany [21, 35, 42, 43, 46] , four studies in Spain [31, 38, 49, 52] , and three studies in and Japan [53, 58, 62], Belgium [18, 19, 22] and China [47, 48, 51] . Twenty-nine studies did not report the response rate [15-17, 20, 24, 26-30, 32-34, 38, 40-43, 45, 47, 48, 50, 51, 55-59, 62] , nine studies did not report HCWs' age [17, 18, 21, 23, 32, 33, 36, 41, 48] , eight studies did not report sex distribution [16, 18, 21, 25, 32, 33, 41, 48] and five studies did not report data collection time [17, 36, [14] . Regarding the study design, 26 studies were cross-sectional studies [14, 15, 18, 19, 21, 23-25, 27-32, 34-37, 39, 44, 47, 52, 54, 58, 60, 61] , 20 studies were prevalence studies [17, 26, 33, 38, 40-43, 45, 46, 48-51, 53, 55, 56, 57, 59, 62] , and three studies were cohort studies [16, 20, 22] . All studies except one [31] used a convenience sample, while response rate ranged from 47.7% [19] to 100% [36, 60] . Forty-two studies were conducted in hospitals [15-24, 26, 27, 29-48, 50-62] , four studies in primary care facilities and hospitals [14, 25, 28, 49] , two studies in primary care facilities [35, 62] and one study in cancer centers [59] . Thirty-five studies were published in journals , while 14 studies in pre-print services [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] .

Validity assessment (sensitivity and specificity) for the antibodies tests used in the included studies according to the manufacturers data are presented in Web Table 2 . Sensitivity ranged from 50% to 100%, while specificity from 80.5% to 100%.

Quality assessment of prevalence studies, cross-sectional studies and cohort studies are shown in Web Tables 3, 4, and 5 respectively. Quality was moderate in 37 studies, good in 10 studies, and poor in two studies. Regarding prevalence studies, 16 were at moderate risk of bias, three were at low risk and one was at high risk. Moreover, 20 cross-sectional studies were at moderate risk of bias, five were at low risk and one was at high risk. Two cohort studies were at low risk of bias and one was at moderate risk.

We applied a random effect model to estimate pooled prevalence since the heterogeneity between results was very high (I 2 =99.34, p-value for the Hedges Q statistic < 0.001). The estimated overall seroprevalence of SARS-CoV-2 antibodies among HCWs was 8.7% (95% CI: 6.7-10.9%) ( Figure 2 ). Seroprevalence among studies ranged from 0% to 45.3%.

According to subgroup analysis, seroprevalence of SARS-CoV-2 antibodies was higher for the studies with poor quality (11.6% [95% CI: 0.7-32.7%]) compared to those with moderate quality (8.8% [95% CI: 6.0-12%]) and good quality (7.9% [95% CI: 4.1-12.8%]). Moreover, seroprevalence was higher for the studies that were published in journals (9% [95% CI: 6.7-11.6%]) compared to those in pre-print services ( 

J o u r n a l P r e -p r o o f on the overall seroprevalence, which varied between 8.2% (95% CI: 6.2-10.3%), with Hoolihan et al. [16] excluded, and 9.0% (95% CI: 6.9-11.2%), with Nakamura et al. [53] excluded (Web Figure 1 ).

Egger's test (p=0.0001) and the asymmetrical shape of the funnel plot (Web Figure 2) implied potential publication bias.

Twenty-seven studies [14, 15, 18, 19, 21-25, 27-32, 34-37, 39, 44, 47, 52, 54, 58, 60, 61] investigated factors associated with SARS-CoV-2 antibodies positivity and 13 studies found associations [14, 18, Three studies [14, 24, 34] found that HCWs self-reported belief that (s)he previously had COVID-19 (ORs range from 1.23 to 5.67) is associated with SARS-CoV-2 antibodies positivity. Similar results found for HCWs with a previous positive Polymerase Chain Reaction (PCR) test (OR=1.52, 95% CI=1.44-1.60 in one study [14] and p<0.001 in another study [34] ). Also, two studies [18, 36] found that household contact with suspected or confirmed COVID-19 patients increases the probability of a positive SARS-CoV-2 antibodies test in HCWs (OR=3.15, 95% CI=2.33-4.25 in one study [18] and p=0.008 in another study [36] ).

To our knowledge, this is the first systematic review and meta-analysis that estimates the overall seroprevalence of SARS-CoV-2 antibodies among HCWs in screening settings. We found that the overall seroprevalence was 8.7% with a wide range among studies from 0% to 45.3%. Population-based and community-based studies in USA showed a great variability in seroprevalence of SARS-CoV-2 antibodies from 1.1% to 14.4% [63] [64] [65] [66] [67] . Similar studies in Europe [68-70] and China [71] found very different seroprevalence in the general population ranging from 0.23% to 10.9%. These differences in seroprevalence among studies may be attributable to several reasons, e.g. different study populations, different antibodies tests with variation in sensitivity and specificity, different study designs, different lockdown and quarantine measures, different data collection time period etc. Moreover, according to our subgroup analysis, seroprevalence of SARS-CoV-2 antibodies was higher for the studies with poor quality (11.6%) compared to those with moderate quality (8.8%) and good quality (7.9%) indicating that difference in studies quality could be also a significant reason for difference in seroprevalence.

Our subgroup analysis identified that seroprevalence was higher in studies that were conducted in North America (12.7%) compared to those in Europe (8.5%), Africa (8.2%), and Asia (4%). This finding is in accordance with a meta-analysis [3] that found that the According to our review, household contact with a suspected or confirmed COVID-19 patients is associated with positive SARS-CoV-2 antibodies test in HCWs [18, 36] . Also, HCWs self-reported belief that (s)he previously had COVID-19 is associated with SARS-CoV-2 antibodies positivity [14, 24, 34] . HCWs are exposed to SARS-CoV-2 not only in clinical settings but also in their house or in social meetings, joint meals, and office spaces with friends or colleagues. In fact, as community transmission increases, the risk of SARS-CoV-2 exposure for HCWs is higher outside of the clinical settings through household contacts with infected COVID-19 patients or interaction with others in areas with active, unmitigated transmission [92-94].

We found that a previous positive PCR test increases the probability of a positive SARS-CoV-2 antibodies test in HCWs [14, 34] . SARS-CoV-2 antibodies tests identify previous SARS-CoV-2 infection but many issues are still controversial. For example, the sensitivity of J o u r n a l P r e -p r o o f these tests is too low in the first week since symptom onset but increases ≥15 days after the onset of symptoms [5] . Also, the duration of antibody rises is unknown since the data >35 days after the onset of symptoms are very scarce [5] . Moreover, Gould and Wilson [101] found that Black workers experience higher SARS-CoV-2 seroprevalence than Whites. This disparity may be attributable to several reasons, e.g. work conditions, economic inequality, high population density, limited access to health care services, health insurance etc. There is a need for strategies tailored to the culture of minority groups and organized by local minority leaders, who can mobilize individuals to participate in screening tests, and tracing and quarantining of COVID-19 contacts to avoid additional

Our study has several limitations. First, 14 out of 49 included studies were published in preprint services which do not apply peer-review process. Nevertheless, we assessed studies quality and we performed subgroup analysis according to publication type (journal or preprint service) and studies quality. Second, the heterogeneity between results was very high.

We performed random effects model and subgroups analysis to overcome this limitation.

Third, seroprevalence reported in studies could be underestimated or overestimated J o u r n a l P r e -p r o o f depending on the applied antibody test. Validity (sensitivity and specificity) of the antibodies tests have not been reported in most of the included studies. We performed meta-regression analysis with sensitivity and specificity of the antibodies tests according to the manufacturers' data as the moderator variables in order to overcome this limitation. Fourth, time between exposure and antibody testing in studies is unknown and seropositivity may have been missed if testing was too early. This systematic bias could result in an underestimation of the seroprevalence. Last, the data regarding the factors that are associated with the seroprevalence of SARS-CoV-2 antibodies were very scarce and we cannot perform meta-analysis; thus a qualitative approach was applied to assess these factors.

Sseroprevalence of SARS-CoV-2 antibodies among HCWs is high indicating that HCWs J o u r n a l P r e -p r o o f for each meta-analysis.

Risk of bias across studies 15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).

Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.

17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.

Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.

Risk of bias within studies 19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).

Results of individual studies 20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.

Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.

Risk of bias across studies 22 Present results of any assessment of risk of bias across studies (see Item 15).

Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16] ).

J o u r n a l P r e -p r o o f Figure 1 DISCUSSION Summary of evidence 24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).

Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).

Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.

14 FUNDING Funding 27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.

14 J o u r n a l P r e -p r o o f Web 

Early transmission dynamics in

of novel coronavirus-infected pneumonia

World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard

COVID-19 in health care workers-A systematic review and meta-analysis

The impact of novel coronavirus SARS-CoV-2 among healthcare workers in hospitals: An aerial overview

Antibody tests for identification of current and past infection with SARS-CoV-2

Point-of-care diagnostic tests for detecting SARS-CoV-2 antibodies: A systematic review and metaanalysis of real-world data

Preferred 11. Ioannidis JP, Patsopoulos NA, Evangelou E. Heterogeneity in meta-analyses of genome-wide association investigations

Bias in meta-analysis detected by a simple, graphical test

Meta-Analyst: software for metaanalysis of binary, continuous and diagnostic data

Northwell Health COVID-19 Research Consortium. Prevalence of SARS-CoV-2 antibodies in health care personnel in the New York City area

Pandemic peak

SARS-CoV-2 antibody screening in healthcare workers in a tertiary centre in North West England

participants who reported a personal protective equipment shortage participants (OR=2.30, 95% CI=1.71-3.10, p<0.001) -Participants' reported belief that (s)he previously had COVID-19

Age, sex, type of occupation, level of exposure to COVID-19 patients

Age, sex, type of occupation -Aged ≥40 years (OR=1.36, 95% CI=1.09-1.60, p=0.006) -Health care assistants

Age, sex, type of occupation

Age, sex, type of occupation, daily contact with patients

COVID-19 confirmed or suspected cases, previously diagnosed with COVID-19 by PCR test, comorbidity, household size

Age, sex, race/ethnicity, primary location of clinical work -African American participants compared to other racial groups (p<0.05) a Univariate

Stubblefield et Age, sex, race/ethnicity, comorbidity, smoking, primary location of clinical work, -Participants' reported belief that (s)he previously had COVID-19 Univariate 2020 [58] seasonal common cold symptoms, history of regular contact with children

Age, sex, type of occupation, patient-related work, COVID-19 patient contact -Patient-related work

Were the two groups similar and recruited from the same population? Χ Χ Χ

Were study participants sampled in an appropriate way? X X X3. Was the sample size adequate? X X X X X X X X 4. Were the study subjects and the setting described in detail? X X X X X X X X X X X X 5. Was the data analysis conducted with sufficient coverage of the identified sample?Were valid methods used for the identification of the condition?Was the condition measured in a standard, reliable way for all participants? Were the study subjects and the setting described in detail?Was the exposure measured in a valid and reliable way?